cholest-5-ene-3,4-diol has been researched along with Chronic Kidney Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Annaert, P; Hasan, M; Kuypers, DRJ; Oswald, S; Vanhove, T | 1 |
| Fujioka, T; Itoh, H; Kawasaki, K; Kishino, S; Mimata, H; Ohno, K; Sato, F; Sato, Y; Suzuki, Y | 1 |
2 other study(ies) available for cholest-5-ene-3,4-diol and Chronic Kidney Failure
| Article | Year |
|---|---|
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
Topics: Adult; Age Factors; Aged; Biological Variation, Population; Biomarkers, Pharmacological; Cytochrome P-450 CYP3A; Female; Genotype; Glomerular Filtration Rate; Graft Rejection; Hematocrit; Humans; Hydroxycholesterols; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Postoperative Period; Preoperative Period; Retrospective Studies; Tacrolimus | 2017 |
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.
Topics: Cytochrome P-450 CYP3A; Female; Humans; Hydroxycholesterols; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Male; Recovery of Function | 2013 |